“We are honored to work with the scientific and clinical experts at MSK Therapeutics Accelerator,” stated Dr. William V. Williams, BriaCell’s President and CEO. “MSK’s deep expertise in cancer therapy ...

As part of the partnership, BioCardia has licensed global exclusive rights to CART-Tech intellectual property for the fields of biotherapeutic intervention. CART-Tech has licensed global exclusive ...

Last year, KFSHRC celebrated a major milestone by completing more than 500 paired kidney transplants since the program was launched in 2011. Since launching its organ transplantation program in 1981, ...

LIXTE will continue to closely monitor developments in the digital asset space and retains the flexibility to adjust its holdings. The Company intends to hold all cryptocurrency assets with a fully ...

X4 expects to use the net proceeds from the financing for continued development towards a potential additional approval of mavorixafor in chronic neutropenia in addition to the commercialization of ...

BaseCamp is the first genetic medicine manufacturing business to receive certification across viral gene delivery, non-viral gene delivery, and cell therapy products WALTHAM, Mass., Aug. 13, 2025 ...

Revenue in the second quarter of 2025 increased 26% to $12.6 million, compared to the second quarter of 2024. Of recent customer engagements, approximately 70% are structured as multi-year lease ...

EMERYVILLE, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its 2025 second quarter and year to date financial results and ...

In connection with the offering, Nasus Pharma’s Ordinary Shares have been approved for listing on the NYSE American LLC. The Ordinary Shares are expected to begin trading on the NYSE American LLC on ...

Event: H.C. Wainwright 27 th Annual Global Investment Conference Location: New York, NY Date and Presentation Time: 12:30 PM Eastern Time on September 10, 2025 Event Format: Presentations and 1-on-1 ...

Net loss was $23.1 million for the second quarter of 2025, resulting in a basic and diluted net loss per share of $0.90. Net loss was $17.5 million for the second quarter of 2024, resulting in basic ...

As of June 30, 2025, the Company had cash and cash equivalents and short-term deposits in the amount of $29.5 million, compared to $15.6 million on December 31, 2024. PolyPid expects that its current ...